Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BeEAM
- Development stage
- Discontinued
- Lead developer
- Centre Léon Bérard
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BeEAM is a high-dose chemotherapy conditioning regimen consisting of bendamustine, etoposide, cytarabine, and melphalan. It was developed by the Centre Léon Bérard as an alternative to the standard BEAM (carmustine, etoposide, cytarabine, and melphalan) regimen, specifically replacing carmustine with bendamustine. The regimen was intended for use prior to autologous stem cell transplantation (ASCT) in patients with first or second chemosensitive relapsed follicular lymphoma. However, a Phase II multicenter study was terminated prematurely due to unacceptable toxicities, including severe infectious complications and veno-occlusive disease. The regimen functions through multiple cytotoxic mechanisms, including DNA alkylation and inhibition of DNA synthesis and repair.
- Other names
- bendamustine + etoposide + cytarabine + melphalanBeEAM conditioning regimen
02
Targets
DNA polymerase familyDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on BeEAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BeEAM.